GREY:IMVIQ - Post by User
Post by
Breakthoroughon Sep 10, 2022 3:43pm
406 Views
Post# 34954448
Interesting (and hidden) data
Interesting (and hidden) dataIf you go to page 19 of last Corporate presentation, you will find, on the left side, "Further evaluating data from SPIReL" (Phase 2a of DLBCL, being Phase 2b the VITALIZE TRIAL). There you can see something not announced till now: mOS In PD-L1+ patients of 17'4 months. That's REALLY GOOD. To have an idea, think that CAR T has generally a mOS of 12 months in the trials (f.ex. JULIET Trial), and 15'8 months in this study of patients treated with commercial CAR T: https://ashpublications.org/bloodadvances/article/4/19/4669/463994/Outcomes-in-patients-with-DLBCL-treated-with Mvp-S+KTR is, needless to say, administered AGTER CAR T (or to people not eligible for CAR T, if I remember well)